 | • レポートコード：B-MOR-040903 • 出版社/出版日：Mordor Intelligence / 2018年2月 • レポート形態：英文、PDF、106ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：医療・バイオ |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、バイオシミラーの世界市場について調べ、バイオシミラーの世界規模、市場動向、市場環境、製品クラス別（モノクローナル抗体、組換ホルモン、組換増殖因子、免疫調整剤、抗炎症剤）分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・バイオシミラーの世界市場インサイト ・バイオシミラーの世界市場環境 ・バイオシミラーの世界市場動向 ・バイオシミラーの世界市場規模 ・バイオシミラーの世界市場規模：製品クラス別（モノクローナル抗体、組換ホルモン、組換増殖因子、免疫調整剤、抗炎症剤） ・バイオシミラーの世界市場：地域別市場規模・分析 ・バイオシミラーの北米市場規模・予測 ・バイオシミラーのアメリカ市場規模・予測 ・バイオシミラーのヨーロッパ市場規模・予測 ・バイオシミラーのアジア市場規模・予測 ・バイオシミラーの日本市場規模・予測 ・バイオシミラーの中国市場規模・予測 ・バイオシミラーのインド市場規模・予測 ・バイオシミラーの韓国市場規模・予測 ・関連企業情報・競争状況 |
The global biosimilar market has been estimated at USD 3474.01 million in 2017. The market is expected to register a CAGR of 43.8% during the forecast period, 2018 to 2023. North America accounted for the largest market share, accounting for approximately 30% of the global market share in 2017, while Asia-Pacific region was estimated to register the fastest CAGR through the forecast period, 2018-2023.
Upcoming Decade to Witness Patent Expiration of Several Biopharmaceuticals
In recent past, several blockbuster biologic drugs of major pharmaceuticals companies expired such as remicade, rituxan, herceptin, Enbrel, lantus and others. In the coming decade, there would be rise in the patent expiration of several existing biological drugs such as Erbitux, Avastin, Orencia and others, which would invite many innovator companies as well as generic manufacturers to offer services specially tailored towards biosimilar. In addition, factors such as cost effectiveness nature of biosimilar, rising acceptance and adoption by various stakeholders with need of diversification in technology and business models drive the global biosimilar market.
High Investments and Longer Timelines are needed
Development and manufacture of biosimilar are more complex compared to generics. A biosimilar takes around 7 to 8 years for its development with high financial investments between USD 100 million and USD 300 million which considerably much higher than the USD 1 million to USD 5 million for generic production. In addition, the manufacturing complexity in each step involves a high degree of variability and hundreds of controlling input parameters for safety and efficacy. At the same time, factors such as lack of definitive standards for approval and adequate profitability given the greater risk with concerns regarding substitutability and interchangeability, many companies are discouraged in investing in this market which impedes the growth of biosimilar market.
North America to Dominate the Market Growth
The global biosimilar market is segmented by products class and geography. By geography, it is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa and South America.
North America accounted for the largest market share, accounting for approximately 30% of the global market share in 2017. The market for North America is highly driven by the presence of many large research laboratories such as Sandoz, Amgen, Teva Pharmaceutical and others. According to a recent report, more than 40 biosimilars are under development, including approximately 20 biosimilars ready to be released into the market, and a large number of biosimilar are in pipeline. Asia Pacific is also expected to grow quickly owing to the immense economic developments and rising biotechnology companies in this region.
Key Developments in the Market
• December 2017: Pfizer received US FDA approval for infliximab biosimilar for all eligible indications
• December 2017: Mylan received US FDA approval for Ogivri, first biosimilar for trastuzumab; co-developed with Biocon
• November 2017: Samsung Bioepis Co Ltd received European Commission marketing approval for Ontruzant, biosimilar for trastuzumab, for the treatment of breast cancer
• November 2017: Samsung Bioepis Co Ltd received approval for Samfenet, a biosimilar for Herceptin to be sold in South Korea
Major Players: PFIZER inc, ELI LILLY AND COMPANY, CELLTRION HEALTHCARE, MYLAN nv, NOVARTIS AG, SAMSUNG BIOEPIS CO ltd, STADA ARZNEIMITTEL ag, TEVA PHARMACEUTICAL INDUSTRIES ltd, INTAS PHARMACEUTICALS ltd AND LG LIFE SCIENCES
Reasons to Purchase this Report
• Current and future biosimilar market outlook in the developed and emerging markets
• Analyzing various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth during the forecast period
• Identify the latest developments, market shares and strategies employed by the major market players.
• 3 months analyst support along with the market estimate sheet in excel
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.
レポート目次1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porters Five Forces
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threats of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Several Blockbuster Biopharmaceuticals Going Off-Patent
6.1.2 Next-Gen Business Models
6.1.3 Market Still In the Early Stage with High Growth Potential
6.1.4 Increasing Demand for Biosimilar Drugs Due To Their Cost-Effectiveness
6.2 Market Restraints
6.2.1 Concerns Regarding Substitutability and Interchangeability
6.2.2 Regulatory Uncertainty
6.2.3 Production Complexity
6.3 Opportunities
6.4 Challenges
7. Market Segmentation
7.1 By Product Class
7.1.1 Monoclonal Antibodies
7.1.1.1 Adalimumab
7.1.1.2 Infliximab
7.1.1.3 Rituximab
7.1.1.4 Trastuzumab
7.1.1.5 Bevacizumab
7.1.1.6 Others
7.1.2 Recombinant Hormones
7.1.2.1 Insulin
7.1.2.2 Human Growth Hormone
7.1.2.3 Follicle-Stimulating Hormone
7.1.2.4 Others
7.1.3 Recombinant Growth Factor
7.1.3.1 Granulocyte Colony-Stimulating Factor
7.1.3.2 Erythropoietin
7.1.3.3 Others
7.1.4 Immunomodulators
7.1.4.1 Interleukins
7.1.4.2 Cytokines
7.1.4.3 Immunomodulatory Imide Drugs (Imids)
7.1.4.4 Others
7.1.5 Anti-Inflammatory Agents
7.1.5.1 Tnf Inhibitors
7.1.5.2 Others
7.2 Segmentation by Geography
7.2.1 North America
7.2.1.1 United States
7.2.1.2 Canada
7.2.1.3 Mexico
7.2.2 Europe
7.2.2.1 France
7.2.2.2 Germany
7.2.2.3 United Kingdom
7.2.2.4 Italy
7.2.2.5 Spain
7.2.2.6 Rest of Europe
7.2.3 Asia-Pacific
7.2.3.1 China
7.2.3.2 Japan
7.2.3.3 India
7.2.3.4 Australia & New Zealand
7.2.3.5 South Korea
7.2.3.6 Rest of Asia-Pacific
7.2.4 Middle East and Africa
7.2.4.1 GCC
7.2.4.2 South Africa
7.2.4.3 Rest of Middle East and Africa
7.2.5 South America
7.2.5.1 Brazil
7.2.5.2 Argentina
7.2.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers and Acquisition Analysis
8.2 Agreements, Collaborations & Partnerships
8.3 New Products Launches
9. Key Players
9.1 Pfizer Inc
9.2 Eli Lilly Aand Company
9.3 Celltrion Healthcare
9.4 Mylan NV
9.5 Novartis AG
9.6 Samsung Bioepis Co Ltd
9.7 Stada Arzneimittel AG
9.8 Teva Pharmaceutical Industries Ltd
9.9 Intas Pharmaceuticals Ltd
9.10 LG Life Sciences
9.11 Others
10. Future of The Market